238 related articles for article (PubMed ID: 17292621)
21. Pharmacokinetics and pharmacodynamics of CHF5074 after short-term administration in healthy subjects.
Imbimbo BP; Frigerio E; Breda M; Fiorentini F; Fernandez M; Sivilia S; Giardino L; Calzà L; Norris D; Casula D; Shenouda M
Alzheimer Dis Assoc Disord; 2013; 27(3):278-86. PubMed ID: 22922591
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological characterization of the novel γ-secretase modulator AS2715348, a potential therapy for Alzheimer's disease, in rodents and nonhuman primates.
Mitani Y; Akashiba H; Saita K; Yarimizu J; Uchino H; Okabe M; Asai M; Yamasaki S; Nozawa T; Ishikawa N; Shitaka Y; Ni K; Matsuoka N
Neuropharmacology; 2014 Apr; 79():412-9. PubMed ID: 24373902
[TBL] [Abstract][Full Text] [Related]
23. Gintonin, a ginseng-derived lysophosphatidic acid receptor ligand, attenuates Alzheimer's disease-related neuropathies: involvement of non-amyloidogenic processing.
Hwang SH; Shin EJ; Shin TJ; Lee BH; Choi SH; Kang J; Kim HJ; Kwon SH; Jang CG; Lee JH; Kim HC; Nah SY
J Alzheimers Dis; 2012; 31(1):207-23. PubMed ID: 22543851
[TBL] [Abstract][Full Text] [Related]
24. Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice.
Jantzen PT; Connor KE; DiCarlo G; Wenk GL; Wallace JL; Rojiani AM; Coppola D; Morgan D; Gordon MN
J Neurosci; 2002 Mar; 22(6):2246-54. PubMed ID: 11896164
[TBL] [Abstract][Full Text] [Related]
25. CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-week, double-blind, placebo-controlled study.
Ross J; Sharma S; Winston J; Nunez M; Bottini G; Franceschi M; Scarpini E; Frigerio E; Fiorentini F; Fernandez M; Sivilia S; Giardino L; Calza L; Norris D; Cicirello H; Casula D; Imbimbo BP
Curr Alzheimer Res; 2013 Sep; 10(7):742-53. PubMed ID: 23968157
[TBL] [Abstract][Full Text] [Related]
26. Transthyretin stabilization by iododiflunisal promotes amyloid-β peptide clearance, decreases its deposition, and ameliorates cognitive deficits in an Alzheimer's disease mouse model.
Ribeiro CA; Oliveira SM; Guido LF; Magalhães A; Valencia G; Arsequell G; Saraiva MJ; Cardoso I
J Alzheimers Dis; 2014; 39(2):357-70. PubMed ID: 24169237
[TBL] [Abstract][Full Text] [Related]
27. Lack of specific amyloid-beta(1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures.
Lanz TA; Fici GJ; Merchant KM
J Pharmacol Exp Ther; 2005 Jan; 312(1):399-406. PubMed ID: 15340006
[TBL] [Abstract][Full Text] [Related]
28. Electrophysiological and metabolic effects of CHF5074 in the hippocampus: protection against in vitro ischemia.
Mango D; Barbato G; Piccirilli S; Panico MB; Feligioni M; Schepisi C; Graziani M; Porrini V; Benarese M; Lanzillotta A; Pizzi M; Pieraccini S; Sironi M; Blandini F; Nicoletti F; Mercuri NB; Imbimbo BP; Nisticò R
Pharmacol Res; 2014 Mar; 81():83-90. PubMed ID: 24630950
[TBL] [Abstract][Full Text] [Related]
29. A modified formulation of Chinese traditional medicine improves memory impairment and reduces Aβ level in the Tg-APPswe/PS1dE9 mouse model of Alzheimer's disease.
Jeon S; Bose S; Hur J; Jun K; Kim YK; Cho KS; Koo BS
J Ethnopharmacol; 2011 Sep; 137(1):783-9. PubMed ID: 21762767
[TBL] [Abstract][Full Text] [Related]
30. CHF5074 (CSP-1103) stabilizes human transthyretin in mice humanized at the transthyretin and retinol-binding protein loci.
Mu Y; Jin S; Shen J; Sugano A; Takaoka Y; Qiang L; Imbimbo BP; Yamamura K; Li Z
FEBS Lett; 2015 Mar; 589(7):849-56. PubMed ID: 25728271
[TBL] [Abstract][Full Text] [Related]
31. Modulation of beta-amyloid metabolism by non-steroidal anti-inflammatory drugs in neuronal cell cultures.
Gasparini L; Rusconi L; Xu H; del Soldato P; Ongini E
J Neurochem; 2004 Jan; 88(2):337-48. PubMed ID: 14690522
[TBL] [Abstract][Full Text] [Related]
32. Deficiency in either COX-1 or COX-2 genes does not affect amyloid beta protein burden in amyloid precursor protein transgenic mice.
Park SA; Chevallier N; Tejwani K; Hung MM; Maruyama H; Golde TE; Koo EH
Biochem Biophys Res Commun; 2016 Sep; 478(1):286-292. PubMed ID: 27425247
[TBL] [Abstract][Full Text] [Related]
33. Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals.
Galasko DR; Graff-Radford N; May S; Hendrix S; Cottrell BA; Sagi SA; Mather G; Laughlin M; Zavitz KH; Swabb E; Golde TE; Murphy MP; Koo EH
Alzheimer Dis Assoc Disord; 2007; 21(4):292-9. PubMed ID: 18090435
[TBL] [Abstract][Full Text] [Related]
34. Selective modulation of amyloid-beta peptide degradation by flurbiprofen, fenofibrate, and related compounds regulates Abeta levels.
Abdul-Hay SO; Edirisinghe P; Thatcher GR
J Neurochem; 2009 Nov; 111(3):683-95. PubMed ID: 19702658
[TBL] [Abstract][Full Text] [Related]
35. NO-flurbiprofen reduces amyloid-beta, is neuroprotective in cell culture, and enhances cognition in response to cholinergic blockade.
Abdul-Hay SO; Luo J; Ashghodom RT; Thatcher GR
J Neurochem; 2009 Nov; 111(3):766-76. PubMed ID: 19702655
[TBL] [Abstract][Full Text] [Related]
36. The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells.
Quann EJ; Khwaja F; Zavitz KH; Djakiew D
Cancer Res; 2007 Apr; 67(7):3254-62. PubMed ID: 17409433
[TBL] [Abstract][Full Text] [Related]
37. Inhibitors of Rho-kinase modulate amyloid-beta (Abeta) secretion but lack selectivity for Abeta42.
Leuchtenberger S; Kummer MP; Kukar T; Czirr E; Teusch N; Sagi SA; Berdeaux R; Pietrzik CU; Ladd TB; Golde TE; Koo EH; Weggen S
J Neurochem; 2006 Jan; 96(2):355-65. PubMed ID: 16300630
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of fatty acid amide hydrolase and cyclooxygenase by the N-(3-methylpyridin-2-yl)amide derivatives of flurbiprofen and naproxen.
Cipriano M; Björklund E; Wilson AA; Congiu C; Onnis V; Fowler CJ
Eur J Pharmacol; 2013 Nov; 720(1-3):383-90. PubMed ID: 24120370
[TBL] [Abstract][Full Text] [Related]
39. Analgesic Effect of the Newly Developed S(+)-Flurbiprofen Plaster on Inflammatory Pain in a Rat Adjuvant-Induced Arthritis Model.
Sugimoto M; Toda Y; Hori M; Mitani A; Ichihara T; Sekine S; Hirose T; Endo H; Futaki N; Kaku S; Otsuka N; Matsumoto H
Drug Dev Res; 2016 Feb; 77(1):20-8. PubMed ID: 26763139
[TBL] [Abstract][Full Text] [Related]
40. Chronic treatment with a novel γ-secretase modulator, JNJ-40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease.
Van Broeck B; Chen JM; Tréton G; Desmidt M; Hopf C; Ramsden N; Karran E; Mercken M; Rowley A
Br J Pharmacol; 2011 May; 163(2):375-89. PubMed ID: 21232036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
